Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702532 · ClinicalTrials.gov registry record · Phase 3
Nicotine Mouth Film for Craving Relief.
A Phase 3 study of Smoking Cessation, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 2
- Study locations
NCT01702532 is a Phase 3 study of Smoking Cessation that has completed, run by GlaxoSmithKline. The registered enrollment target is 320 participants, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (32% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01702532, a Phase 3 study of Smoking Cessation, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 2
- Study locations
Study Summary
Nicotine mouth film is a new dosage form of nicotine replacement therapy. The purpose of this study is to investigate the craving relief efficacy of nicotine mouth film by comparing mint nicotine mouth film to nicotine lozenge in light smokers using the provoked craving model. The cues used to provoke a craving episode will be the sight and smell of a lit cigarette and the manipulations required to light a cigarette. The smokers will be denied access to cigarettes for 4 hours prior to the provoked craving session in order to precipitate nicotine withdrawal and an increase level of cigarette craving.
Conditions Studied
Interventions
- DRUG Nicotine
Study Locations (2)
California
- Los Angeles Clinical Trials - Burbank
Kentucky
- Central Kentucky Research Associates, Inc. - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01702532
The ClinicalTrials.gov registry entry for NCT01702532 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (32% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which Nicotine is the first listed.
NCT01702532 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01702532 about?
NCT01702532 is a clinical study titled "Nicotine Mouth Film for Craving Relief.". Nicotine mouth film is a new dosage form of nicotine replacement therapy. The purpose of this study is to investigate the craving relief efficacy of nicotine mouth film by comparing mint nicotine mouth film to nicotine lozenge in light smokers using the provoked craving model. The cues used to provo...
What is the current status of trial NCT01702532?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2012-09. Estimated completion is 2012-12.
What conditions does trial NCT01702532 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT01702532?
The interventions under investigation include: Nicotine (DRUG).
Who is sponsoring clinical trial NCT01702532?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01702532 being conducted?
This trial has 2 study locations across California, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.